1300031-61-1

Basic information

• Product Name: [3-(3,5-diMethyl-4-isoxazolyl)-4-(Methyloxy)phenyl]aMine
• Synonyms: [3-(3,5-diMethyl-4-isoxazolyl)-4-(Methyloxy)phenyl]aMine;3-(3,5-dimethylisoxazol-4-yl)-4-methoxyaniline
• CAS NO: 1300031-61-1
• Molecular Formula: C₁₂H₁₄N₂O₂
• Molecular Weight: 218.25176
• Mol File: 1300031-61-1.mol

Chemical Properties

• Boiling Point: 343.3±42.0 °C(Predicted)
• Appearance: /
• Density: 1.151±0.06 g/cm3(Predicted)
• PKA: 4.55±0.10(Predicted)
• CAS DataBase Reference: [3-(3,5-diMethyl-4-isoxazolyl)-4-(Methyloxy)phenyl]aMine(CAS DataBase Reference)
• NIST Chemistry Reference: [3-(3,5-diMethyl-4-isoxazolyl)-4-(Methyloxy)phenyl]aMine(1300031-61-1)
• EPA Substance Registry System: [3-(3,5-diMethyl-4-isoxazolyl)-4-(Methyloxy)phenyl]aMine(1300031-61-1)

Safety Data

• Hazardous Substances Data: 1300031-61-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
[3-(3,5-diMethyl-4-isoxazolyl)-4-(Methyloxy)phenyl]aMine is used as a potential active pharmaceutical ingredient for [application reason] due to its unique chemical structure and biological properties.
Used in Agrochemical Industry:
In the agrochemical industry, [3-(3,5-diMethyl-4-isoxazolyl)-4-(Methyloxy)phenyl]aMine is used as a [application type] for [application reason], leveraging its specific chemical and biological characteristics.
Used in Materials Science:
[3-(3,5-diMethyl-4-isoxazolyl)-4-(Methyloxy)phenyl]aMine is utilized as a [application type] in materials science for [application reason], taking advantage of its distinctive properties.
(Note: The "application type" and "application reason" would need to be filled in with specific details based on the compound's properties and potential uses once they are identified through further research and development.)

Upstream product

• 16114-47-9 3,5-dimethylisoxazole-4-boronic acid 
• 5399-03-1 2-iodo-1-methoxy-4-nitrobenzene 
• 1300031-62-2 3,5-dimethyl-4-[2-(methyloxy)-5-nitrophenyl]isoxazole 
• 10558-25-5 4-bromo-3,5-dimethyl-1,2-oxazole 
• 832114-00-8 3,5-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoxazole 
• 74587-12-5 3-iodo-4-methoxyaniline 

Downstream Products

• 1300031-60-0 1,3-diethyl 2-([[3-(3,5-dimethyl-1,2-oxazol-4-yl)-4-methoxyphenyl]amino]methylidene)propanedioate 
• 1300031-49-5 I-BET151 
• 1300031-57-5 4-chloro-7-(3,5-dimethyl-4-isoxazolyl)-6-(methyloxy)-3-quinolinecarboxamide 
• 1300737-57-8 Ethyl 4-{[2-(1,1-di methylethyl)phenyl]amino}-7-(3,5-dimethyl-4-isoxazolyl)-6-(methoxy)-3-quinolinecarboxylate 
• 1300737-63-6 4-{[2-(1,1-dimethylethyl)phenyl]amino}-7-(3,5-dimethyl-4-isoxazolyl)-6-(methoxy)-3-quinolinecarboxylic acid hydrochloride 
• 1300737-69-2 7-(3,5-dimethyl-4-isoxazolyl)-6-(methyloxy)-4-{[(1R)-1-(2-pyridinyl)ethyl]amino}-3-quinolinecarboxamide 

Relevant articles and documents

METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE

The present disclosure relates to compounds and methods for modulating the expression of dmpk, and treating diseases and conditions in which dmpk plays an active role. The compound can be a transcription modulator molecule having a first terminus, a second terminus, and oligomeric backbone, wherein: a) the first terminus comprises a DNA-binding moiety capable of noncovalently binding to a nucleotide repeat sequence CAG or CTG; b) the second terminus comprises a protein-binding moiety binding to a regulatory molecule that modulates an expression of a gene comprising the nucleotide repeat sequence CAG or CTG; and c) the oligomeric backbone comprising a linker between the first terminus and the second terminus.

QUINOLINE DERIVATIVES AS BROMODOMAIN INHIBITORS

Provided is a novel quinoline derivative inhibiting the bromodomain and extra terminal domain (BET) proteins, and a pharmaceutical composition comprising the same which can be useful for prevention or treatment of a precancerous transformation or a cancer.

OXAZOLO[5,4-C]QUINOLIN-2-ONE COMPOUNDS AS BROMODOMAIN INHIBITORS

The present invention relates to compounds useful as bromodomain inhibitors. The invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and methods of using said compounds and compositions in the treatment of various diseases and disorders.

7-(3,5-Dimethyl-4-Isoxazolyl)-8-(Methyloxy)-1H-Imidazo[4,5-C]Quinoline Derivatives

Novel quinoline compounds pharmaceutical compositions containing such compounds and their use in therapy.

4-(8-METHOXY-1-((1-METHOXYPROPAN-2-YL)-2-(TETRAHYDRO-2H-PYRAN-4-YL)-1 H-IMIDAZO[4,5-C]QUINOLIN-7-YL)-3,5-DIMETHYLISOXAZOLE AND ITS USE AS BROMODOMAIN INHIBITOR

Novel quinoline compounds of formula (I), pharmaceutical compositions containing such compounds and their use in therapy, as bromodomain inhibitors.

From ApoA1 upregulation to BET family bromodomain inhibition: Discovery of I-BET151

The discovery, synthesis and biological evaluation of a novel series of 7-isoxazoloquinolines is described. Several analogs are shown to increase ApoA1 expression within the nanomolar range in the human hepatic cell line HepG2.

NOVEL COMPOUNDS

Novel quinoline compounds pharmaceutical compositions containing such compounds and their use in therapy.

Imidazo [4, 5-C] Quinoline Derivatives As Bromodomain Inhibitors

Novel compounds of formula (I) and salts thereof, pharmaceutical compositions containing such compounds and their use in therapy.

IMIDAZO [4, 5-C] QUINOLINE DERIVATES AS BROMODOMAIN INHIBITORS

Novel compounds of Formula (I) and salts thereof, pharmaceutical compositions containing such compounds and their use in therapy.